ERBB2 and breast cancer: Median time from MBC to LMD differed by subtype with longer time to LMD in patients with HR+/HER2− (20.5 months) and HER2+BC (17.5 months) vs. shorter time in patients with TNBC (10.5 months) (p < 0.01).